Egetis (Q3 review): Focus on US application - Redeye
Bildkälla: Stockfoto

Egetis (Q3 review): Focus on US application - Redeye

Redeye returns with an updated view of Egetis Therapeutics following the Q3 report and the recent ReTRIACt readout.

Redeye returns with an updated view of Egetis Therapeutics following the Q3 report and the recent ReTRIACt readout.
Börsvärldens nyhetsbrev